Dark

CHRS
Coherus Oncology, Inc. Common Stock
stock NASDAQ

At Close

Jun 9, 2026 3:59:55 PM EDT

1.42USD+0.352%(0.00)691,496

1.22Bid 1.70Ask 0.48Spread

Pre-market

Jun 8, 2026 9:00:30 AM EDT

1.49USD+4.930%(+0.07)0

After-hours

Jun 9, 2026 4:00:30 PM EDT

1.42USD-0.351%(0.00)80,369

OverviewOptionsHistoricalExchangesShortsNews

Jan 10, 2022

07:40AM EST Coherus And Junshi Biosciences Expand Immuno-Oncology Collaboration To Include TIGIT-Targeted Antibody; Coherus To Pay Junshi $35M Upfront, Up To $255M In Milestones And 18% Net Royalty Benzinga

07:30AM EST Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combinationin clinical trials in multiple tumor types GlobeNewswire Inc

Jan 7, 2022

01:04PM EST Coherus BioSciences Reports Secured Credit Financing With Pharmakon Advisors Benzinga

08:30AM EST Coherus BioSciences, Inc. (Coherus or the Company)(Nasdaq: CHRS) today announced that it has entered into a loan agreement withinvestment funds managed by Pharmakon Advisors, LP. GlobeNewswire Inc

Jan 4, 2022

08:33AM EST Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that senior management will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9 a.m. EST / 6 a.m. PST. GlobeNewswire Inc

Dec 20, 2021

10:01AM EST Coherus BioSciences shares were trading higher after the company announced FDA approval of YUSIMRY. Benzinga

07:59AM EST - Approved for all eligible indications of the reference biological product, Humira (adalimumab) - GlobeNewswire Inc

05:05AM EST Coherus Biosciences Received FDA Approval for Yusimry on Sunday Under BLA #761216 Benzinga

Dec 17, 2021

09:09AM EST Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Theresa LaVallee, Ph.D. as its Chief Development Officer. Dr. LaVallee will serve as a member of the Companys executive leadership team and oversee all regulatory matters and product development functions, reporting to Denny Lanfear, President and CEO of Coherus. GlobeNewswire Inc

Dec 16, 2021

04:30PM EST Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire Inc

Dec 13, 2021

07:04AM EST Junshi Biosciences and Coherus Announce Interim Overall Survival Results Of CHOICE-01, A Phase 3 Clinical Trial Evaluating Toripalimab In Combination With Chemotherapy As First-Line Treatment For Non-Small Cell Lung Cancer Benzinga

07:00AM EST Junshi Biosciences and Coherus Announce Positive Interim Overall GlobeNewswire Inc

07:00AM EST Coherus and Junshi Biosciences Announce Positive Interim Overall GlobeNewswire Inc

Dec 2, 2021

12:02PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

Nov 15, 2021

11:09AM EST Coherus BioSciences, Shanghai Junshi Biosciences Report FDA Granted Orphan Drug Designation For Torpalimab For Treatment Of Esophageal Cancer Benzinga

08:42AM EST Coherus And Junshi Biosciences: Toripalimab Granted Orphan Drug Designation In U.S. For Esophageal Cancer RTTNews

08:30AM EST Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan GlobeNewswire Inc

08:30AM EST Junshi Biosciences and Coherus Announce Toripalimab Granted Orphan GlobeNewswire Inc

Nov 9, 2021

11:26AM EST HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $30 Benzinga

11:16AM EST Recap: Coherus BioSciences Q3 Earnings Benzinga

11:06AM EST Coherus BioSciences Q3 EPS $(0.34) Misses $(0.22) Estimate, Sales $82.50M Miss $91.31M Estimate Benzinga

Nov 8, 2021

04:01PM EST Key milestones achieved driving near-term commercial product portfolio expansion GlobeNewswire Inc

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Nov 5, 2021

09:43AM EDT Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement For UDENYCA In 340B Hospital Setting Through Year-End 2022 Benzinga

08:30AM EDT Coherus BioSciences, Inc.(Coherus, Nasdaq: CHRS), today announced that the Centers for Medicare & Medicaid Services (CMS) will continue to provide increased Medicare reimbursement in the 340B outpatient hospital setting through year-end 2022 for 28 drugs, biologics and devices impacted by the COVID-19 public health emergency, including UDENYCA (pegfilgrastim-cbqv). GlobeNewswire Inc

Nov 1, 2021

07:43AM EDT Junshi Biosciences, Coherus Announce FDA Acceptance Of BLA Filing For Toripalimab For Nasopharyngeal Carcinoma RTTNews

07:31AM EDT Junshi Biosciences And Coherus Announce FDA Acceptance Of BLA Filing For Toripalimab For Treatment Of Nasopharyngeal Carcinoma Benzinga

07:30AM EDT -- FDA has granted the toripalimab BLA Priority Review with a target action date of April 2022 GlobeNewswire Inc

07:30AM EDT Junshi Biosciences and Coherus Announce FDA Acceptance of BLA GlobeNewswire Inc

Oct 29, 2021

04:12PM EDT Coherus BioSciences, Inc.(Coherus, Nasdaq: CHRS), today announced that its third quarter 2021 financial results will be released after market close onMonday, November 8, 2021. Starting at5 p.m. ET, Coherus management team will host a conference call and webcast to discuss financial results and provide a general business update. GlobeNewswire Inc

Oct 11, 2021

08:30AM EDT It is with profound sadness that Coherus BioSciences, Inc.(Nasdaq: CHRS) announces the unexpected passing of board member Alan C. Mendelson. He had been a director of the Company since January 2021 and had previously served as external legal counsel since its founding in 2010. GlobeNewswire Inc

Oct 5, 2021

08:17AM EDT CORRECTION: The Ticker For Coherus BioSciences Is 'CHRS' Benzinga

08:00AM EDT - UDENYCA On-Body Injector (OBI) Achieved Both Pharmacokinetic and Pharmacodynamic Bioequivalence in Randomized Clinical Trial GlobeNewswire Inc

Oct 4, 2021

08:03AM EDT Coherus BioSciences Highlights Oct. 1 Presentation Of Results From COLUMBUS-AMD Trial Benzinga

08:00AM EDT Positive Results of Clinical Trial Comparing GlobeNewswire Inc

Oct 1, 2021

01:11PM EDT Coherus Announces BLA Filing For Lucentis (ranibizumab) Biosimilar Candidate Accepted By FDA For Review Benzinga

01:09PM EDT -- FDA has set a target action date of August 2, 2022 for the CHS-201 BLA GlobeNewswire Inc

Sep 29, 2021

04:30PM EDT It is with profound sadness that Coherus BioSciences, Inc.(Nasdaq: CHRS) announces the passing of board member Samuel Nussbaum, M.D. During his distinguished career, Dr. Nussbaum worked as a physician, researcher, professor, and healthcare executive. He had been a director of the Company since May 2018. GlobeNewswire Inc

Sep 24, 2021

04:15PM EDT Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire Inc

Sep 17, 2021

07:39AM EDT Junshi Biosciences, Coherus Share Toripalimab Survival Data In Esophageal Cancer Benzinga

Sep 16, 2021

10:50PM EDT Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences Inc. (CHRS) said an interim results from Phase 3 clinical trial has provided strong evidence that addition of toripalimab to chemotherapy as a first-line treatment for advanced or metastatic esophageal squamous cell carcinoma patients has superior progression free survival and overall survival than chemotherapy alone. RTTNews

06:28PM EDT - Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 - GlobeNewswire Inc

Sep 15, 2021

08:32AM EDT Coherus, Junshi Biosciences Announce Results From Phase 3 Study Of Toripalimab Published In September Issue Of Nature Medicine Benzinga

08:30AM EDT Coherus and Junshi Biosciences Announce Results from Phase 3 Study GlobeNewswire Inc

Sep 14, 2021

07:50AM EDT The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout Benzinga

Sep 13, 2021

08:56PM EDT Positive Interim Results of CHOICE-01 Study Evaluating Junshi GlobeNewswire Inc

08:35PM EDT Positive Interim Results of CHOICE-01 Study Evaluating Coherus' GlobeNewswire Inc

Sep 12, 2021

04:04PM EDT The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs Benzinga

Sep 10, 2021

08:45AM EDT Coherus BioSciences, Inc.(Coherus, Nasdaq: CHRS), today announced that senior management will present at the 23rd Annual H.C. Wainwright Global Investment Conference. The presentation will be made available at 7 a.m. ET on Tuesday, September 14, 2021, during the virtual conference. GlobeNewswire Inc

Sep 8, 2021

08:30AM EDT Coherus BioSciences Announces Upcoming Medical Conference GlobeNewswire Inc

Sep 1, 2021

08:04AM EDT Coherus, Junshi Report Completion Of Rolling Biologics License Application Submission To FDA For Toripalimab For Treatment Of Nasopharyngeal Carcinoma Benzinga

08:01AM EDT Coherus and Junshi Biosciences Announce Completion of Rolling BLA GlobeNewswire Inc

Aug 27, 2021

04:15PM EDT Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire Inc

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

07:27AM EDT Coherus and Junshi Biosciences Late Yesterday Announcd Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer Benzinga

06:01AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 5.30 A.M. EDT). RTTNews

Aug 18, 2021

10:59PM EDT Coherus BioSciences Inc. (CHRS) and Shanghai Junshi Biosciences Co., Ltd. announced positive interim results from a phase 3 clinical trial, which evaluated toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer or NSCLC. RTTNews

09:10PM EDT Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone GlobeNewswire Inc

Aug 12, 2021

08:01AM EDT Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough GlobeNewswire Inc

Aug 5, 2021

04:30PM EDT Coherus BioSciences Q2 EPS $(0.36) Misses $(0.17) Estimate, Sales $87.64M Miss $89.81M Estimate Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 26, 2021

04:31PM EDT Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021. Starting at 5 p.m. ET, Coherus management team will host a conference call and webcast to discuss financial results and provide a general business update. GlobeNewswire Inc

Jul 23, 2021

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

06:42AM EDT HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Raises Price Target to $36 Benzinga

Jul 21, 2021

09:15AM EDT Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., GlobeNewswire Inc

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 12, 2021

08:31PM EDT Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire Inc

Jun 4, 2021

04:01PM EDT Shanghai Junshi Biosciences Co., Ltd(Junshi Biosciences, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that the companies will host a virtual investor event on Monday, June 7, 2021 at 6 p.m. Eastern Time to discuss toripalimab clinical data from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. GlobeNewswire Inc

10:01AM EDT Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial Benzinga

09:39AM EDT The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact Benzinga

Jun 3, 2021

08:46PM EDT In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups GlobeNewswire Inc

05:09PM EDT Coherus, Junshi Bio Report Toripalimab In Combo With Chemo Met Primary Endpoint As First-Line Treatment For Recurrent, Metastatic Nasopharyngeal Carcinoma Benzinga

05:00PM EDT In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups GlobeNewswire Inc

May 27, 2021

08:24AM EDT The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs Benzinga

May 26, 2021

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

May 25, 2021

07:53AM EDT The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal Benzinga

May 20, 2021

08:27AM EDT The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks Benzinga

May 17, 2021

07:19AM EDT Barclays Maintains Overweight on Coherus BioSciences, Lowers Price Target to $24 Benzinga

May 7, 2021

04:01PM EDT Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. EST / 10:15 a.m. PST. GlobeNewswire Inc

07:47AM EDT HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $26 Benzinga

May 6, 2021

05:47PM EDT Coherus BioSciences: Q1 Earnings Insights Benzinga

04:43PM EDT Coherus BioSciences Q1 EPS $0.01 Misses $0.06 Estimate, Sales $83.03M Miss $96.00M Estimate Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

Apr 30, 2021

04:15PM EDT Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire Inc

08:15AM EDT Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be released after market close on Thursday, May 6, 2021. Starting at 4:30 p.m. ET, Coherus management team will host a conference call and webcast to discuss financial results and provide a general business update. GlobeNewswire Inc

Apr 29, 2021

07:38AM EDT Junshi Biosciences And Coherus To Present Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data At 2021 ASCO Annual Meeting Jun. 6 Benzinga

07:30AM EDT Junshi Biosciences and Coherus Announce Toripalimab First-Line GlobeNewswire Inc

Apr 26, 2021

01:54PM EDT 5 Value Stocks In The Healthcare Sector Benzinga

Apr 23, 2021

10:12AM EDT Coherus Shares Are Trading Higher As Toripalimab Shows Survival Benefit In Late-Stage Esophageal Cancer Study Benzinga

08:02AM EDT Coherus Announces Toripalimab Achieved Primary Endpoints Of Progression Free Survival And Overall Survival In Interim Analysis Of Phase 3 Clinical Trial In First-Line Esophageal Squamous Cell Carcinoma Benzinga

08:00AM EDT Coherus Announces Toripalimab Achieved Primary Endpoints of GlobeNewswire Inc

Apr 20, 2021

08:00AM EDT Coherus Announces Closing of Sale of Common Stock to GlobeNewswire Inc

Apr 14, 2021

07:51AM EDT The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead Benzinga

Apr 13, 2021

08:16AM EDT The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga

Apr 6, 2021

08:05AM EDT The Daily Biotech Pulse: Illumina Lights Up, Cara Soars On Index Inclusion, Novavax Starts Crossover Vaccine Study, Turning Point Data Readout Benzinga

Mar 31, 2021

07:41AM EDT The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO Benzinga

Mar 3, 2021

06:45AM EST Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma Benzinga

06:45AM EST Junshi Biosciences and Coherus BioSciences Announce Initiation of GlobeNewswire Inc

Feb 25, 2021

08:45AM EST Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in March. GlobeNewswire Inc

06:20AM EST HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $29 Benzinga

Feb 24, 2021

04:14PM EST Coherus BioSciences Q4 EPS $0.12 Misses $0.23 Estimate, Sales $110.42M Miss $115.12M Estimate Benzinga

04:01PM EST Coherus BioSciences Reports Fourth Quarter and Full Year 2020 GlobeNewswire Inc

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

03:35AM EST Earnings Scheduled For February 24, 2021 Benzinga

Feb 18, 2021

08:30AM EST Coherus BioSciences to Report Fourth Quarter and Full Year 2020 GlobeNewswire Inc

Feb 17, 2021

10:00AM EST FDA Accepts Coherus Biosciences' Adalimumab Biosimilar Application For Review Benzinga

07:31AM EST Coherus' Biologics License Application Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review Benzinga

07:30AM EST Coherus BLA Filing for Adalimumab Biosimilar GlobeNewswire Inc

Feb 16, 2021

08:36AM EST Coherus Says CFO To Resign Effective March 7, Names McDavid Stilwell As CFO Benzinga

08:00AM EST Coherus BioSciences, Inc. (Nasdaq: CHRS, the Company, Coherus) announced that Chief Financial Officer Jean-Frdric Viret, Ph.D. will resign from Coherus effective March 7, 2021 to pursue another opportunity. McDavid Stilwell has been appointed to succeed Dr. Viret as CFO. GlobeNewswire Inc

Feb 2, 2021

08:32AM EST Coherus BioSciences To Receive $50M Strategic Investment From Immuno-Oncology Partner Junshi Biosciences Benzinga

08:30AM EST A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (Coherus) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (Junshi Biosciences) intends to make a strategic investment of $50 million in Coherus pursuant to the terms of the definitive stock purchase agreement. GlobeNewswire Inc

Feb 1, 2021

07:56AM EST UPDATE: Junshi To Receive $150M Upfront Payment And 20% Royalty On Annual Net Sales Of Toripalimab, Will Receive Up to Aggregate $380M In One-Time Payments For Milestones; For JS006 And JS108-1, Junshi To Receive $35M Opt-In Payment And 18% Royalty Benzinga

07:53AM EST -- Junshi Biosciences to receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised) in US and Canada -- The first toripalimab BLA to be filed with the US FDA for nasopharyngeal carcinoma later this year GlobeNewswire Inc

05:32AM EST Coherus to Pay $150M Upfront to Junshi Biosciences for U.S., Canada Rights to Toripalimab, an Extensively Studied, Late-stage Anti-pd-1 Antibody Benzinga

05:30AM EST - Coherus to pay $150 million upfront for U.S. and Canada rights to toripalimab, an extensively studied, late-stage anti-PD-1 antibody- First U.S. BLA filing expected this year for nasopharyngeal carcinoma with breakthrough therapy designation- Options to PD-1 combination agents, TIGIT and IL-2, add long-term growth potential- Conference call at 8:00 am Eastern Time today GlobeNewswire Inc

Jan 22, 2021

04:01PM EST Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire Inc

Jan 7, 2021

04:07PM EST Coherus BioSciences Appoints Alan Mendelson And Mark Stolper To Board Of Directors RTTNews

04:01PM EST Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Board of Directors effective January 5, 2021. GlobeNewswire Inc

Jan 5, 2021

04:01PM EST Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that senior management will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. EST / 7:50 a.m. PST. GlobeNewswire Inc

Dec 26, 2020

09:16AM EST The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks Benzinga

Dec 21, 2020

04:02PM EST Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire Inc

09:54AM EST A Look Into Healthcare Sector Value Stocks Benzinga

Nov 20, 2020

04:01PM EST Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire Inc

Nov 19, 2020

07:30AM EST Mizuho Maintains Buy on Coherus BioSciences, Lowers Price Target to $30 Benzinga

Nov 9, 2020

09:30AM EST 5 Value Stocks To Watch In The Healthcare Sector Benzinga

Nov 6, 2020

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

06:42AM EST HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $32 Benzinga

Nov 5, 2020

04:13PM EST Coherus BioSciences Q3 EPS $0.33 Misses $0.41 Estimate, Sales $113.55M Miss $122.88M Estimate Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 26, 2020

09:51AM EDT Overview Of Value Stocks In The Healthcare Sector Benzinga

Oct 16, 2020

09:30AM EDT Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire Inc

Oct 5, 2020

09:45AM EDT 5 Value Stocks To Watch In The Healthcare Sector Benzinga

Sep 18, 2020

11:02AM EDT Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire Inc

Aug 20, 2020

02:37PM EDT Coherus Shares Move Lower; UDENYCA Removes Express Scripts National Preferred Formulary Benzinga

Aug 10, 2020

12:58PM EDT Truist Securities Maintains Buy on Coherus BioSciences, Raises Price Target to $30 Benzinga

Aug 7, 2020

06:48AM EDT HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Raises Price Target to $33 Benzinga

Aug 6, 2020

04:35PM EDT Coherus BioSciences Q2 EPS $0.70 Beats $0.33 Estimate, Sales $135.67M Beat $104.95M Estimate Benzinga

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

Aug 3, 2020

04:49PM EDT Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Directors effective July 30, 2020. GlobeNewswire Inc

Jul 27, 2020

01:54AM EDT 5 Value Stocks In The Healthcare Sector Benzinga

Jul 17, 2020

09:30AM EDT Coherus BioSciences Announces New Employment Inducement Grants GlobeNewswire Inc

Jul 16, 2020

09:33AM EDT Benzinga's Top Upgrades, Downgrades For July 16, 2020 Benzinga

09:30AM EDT Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that its second quarter 2020 financial results will be released after market close on Thursday, August 6, 2020. Starting at 4:30 p.m. ET, Coherus management team will host a conference call to discuss financial results and provide a general business update. GlobeNewswire Inc

07:23AM EDT B of A Securities Initiates Coverage On Coherus BioSciences with Neutral Rating, Announces Price Target of $20 Benzinga